PUBLICATION

Fluxapyroxad disrupt erythropoiesis in zebrafish (Danio rerio) embryos

Authors
Chen, X., Qiu, T., Pan, M., Xiao, P., Li, W.
ID
ZDB-PUB-221106-4
Date
2022
Source
Ecotoxicology and environmental safety   247: 114259 (Journal)
Registered Authors
Keywords
Embryo, Fluxapyroxad, Hematotoxicity, SDHIs, Zebrafish
MeSH Terms
  • Amides
  • Animals
  • Erythropoiesis*/genetics
  • Teratogens
  • Zebrafish*/genetics
PubMed
36334343 Full text @ Ecotoxicol. Environ. Saf.
Abstract
Fluxapyroxad, a succinate dehydrogenase inhibitor (SDHI) fungicide, is commercialized worldwide to control a variety of fungal diseases. Growing evidence shows that fluxapyroxad is teratogenic to aquatic organisms. In this study, the influence of fluxapyroxad toward hematopoietic development was evaluated using zebrafish embryos which were exposed to fluxapyroxad (0.03 µM, 0.3 µM and 3 µM) from 3 h post fertilization (hpf) to 3 days post fertilization (dpf). Compared to the control groups, the hemoglobin was ectopic and decreased in response to fluxapyroxad treatment. The transcription levels of genes (hbbe1, hbbe2, and gata1a) involved in erythropoiesis were reduced after exposure to fluxapyroxad. In contrast, the distributions and expression of marker genes for myeloid lineage cells were unaffected by fluxapyroxad exposure. Our data suggested that fluxapyroxad might specifically affect erythropoiesis and hold great promise for the assessment of the toxicity of fluxapyroxad to aquatic organisms.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping